Resveratrol prevents liver damage in MCD-induced steatohepatitis mice by promoting SIGIRR gene transcription

Che, Yuanyuan; Shi, Xu; Zhong, Xiaodan; Zhang, Yutong; Si, RuJia; Li, YaNan; Shi, Ying

doi:10.1016/j.jnutbio.2020.108400

Cited by 22 publications

(13 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sections were approximately 3 μm and stained with hematoxylin and eosin (H&E). The levels of F4/80 and NF-κB(p65) in the tissues were analyzed by immunohistochemistry as previously described [ 24 ]. For the histological diagnosis of NASH, the NAFLD activity score was evaluated by a pathologist using standards as previously described [ 25 ].…”

Section: Methodsmentioning

confidence: 99%

Human umbilical cord mesenchymal stromal cell-derived exosomes protect against MCD-induced NASH in a mouse model

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background and aims Human umbilical cord mesenchymal stem cells (hUC-MSCs) are increasingly being studied in clinical trials of end-stage liver disease because of their good tissue repair and anti-inflammatory effects. hUC-MSC exosomes are vesicles with spherical structures secreted by cells that produce them. The diameter of exosomes is much smaller than that of hUC-MSCs, suggesting that exosomes might be a novel and safer therapeutic product of mesenchymal stem cells. As exosomes have been suggested to have biochemical functions similar to those of hUC-MSCs, this study investigated the efficiency of hUC-MSC-derived exosomes in protecting against nonalcoholic steatohepatitis using an MCD-induced mouse model. Methods Human umbilical cord mesenchymal stem cell-derived exosomes were extracted and purified. The effect of these exosomes on disease progression in an MCD-induced nonalcoholic steatohepatitis mouse model was investigated. Results The results showed that UC-MSC exosomes intravenously transplanted into mice with MCD-induced NASH improved MCD-induced body weight loss and liver damage in a mouse model. Additionally, the inflammatory cytokines in liver tissue were reduced, which may be caused by exosome-induced macrophage anti-inflammatory phenotypes both in vitro and in vivo. In addition, UC-MSC exosomes reversed PPARα level in ox-LDL-treated hepatocytes in vitro and in NASH mouse liver, which had been downregulated. Conclusions UC-MSC exosomes alleviate MCD-induced NASH in mice by regulating the anti-inflammatory phenotype of macrophages and by reversing PPARα protein expression in liver cells, which holds great potential in NASH therapy.

show abstract

Section: Methodsmentioning

confidence: 99%

Human umbilical cord mesenchymal stromal cell-derived exosomes protect against MCD-induced NASH in a mouse model

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…RSV (resveratrol) supplementation in rodents fed with a highfat diet demonstrated an increased number of mitochondria and, in particular, an increase in hepatic decoupling protein 2 expression, which could be involved in the normalization of the hepatic fat content [18]. Resveratrol significantly reduced TAG (triacylglycerols) and cholesterol, as well as the number and size of lipid droplets [19,20]. It would appear that a low dose of resveratrol (0.005%) is more effective than higher doses (0.02%) at reducing the development of hepatic steatosis, along with increases in body weight, plasma TAG levels, and total cholesterol levels [21].…”

Section: Steatosismentioning

confidence: 99%

The Role of Resveratrol in Liver Disease: A Comprehensive Review from In Vitro to Clinical Trials

et al. 2021

View full text Add to dashboard Cite

Many studies have shown that resveratrol has a lot of therapeutic effects on liver disorders. Its administration can significantly increase the survival rate after liver transplantation, reduce fat deposition and ischemia-induced necrosis and apoptosis in Wistar rats. Resveratrol can provide Liver protection against chemical, cholestatic, and alcohol-mediated damage. It can improve glucose metabolism and lipid profile, reduce liver fibrosis, and steatosis. Additionally, it is capable of altering the fatty acid composition of the liver cells. Resveratrol may be a potential treatment option for the management of non-alcoholic fatty liver disease (NAFLD) due to its anti-inflammatory, antioxidant, and calorie-restricting effects. There are also studies that have evaluated the effect of resveratrol on lipid and liver enzyme profiles among patients with metabolic syndrome (MetS) and related disorders. Based on the extent of liver disease worldwide and the need to find new treatment possibilities, this review critically examines current in vitro and in vivo preclinical studies and human clinical studies related to liver protection.

show abstract

“…RES is a polyphenolic compound with various pharmacological effects: antioxidant, anti-inflammatory, and anti-apoptotic, among others ( Chávez et al., 2008 ). In multiple models, RES has been shown to ameliorate liver injury and fibrosis ( Che et al, 2020 ; Cheng et al, 2019 ; Zhu et al, 2020 ). In addition, RES protects against liver injury from iron overload by reducing iron deposition ( Li et al, 2021 ).…”

Section: Discussionmentioning

confidence: 99%

Resveratrol ameliorates iron overload induced liver fibrosis in mice by regulating iron homeostasis

Wang

Jiang

Yang

et al. 2022

PeerJ

View full text Add to dashboard Cite

This study is intended to explore the protective effects of resveratrol (RES) on iron overload-induced liver fibrosis and its mechanism. Iron dextran (50 mg/kg) was injected intraperitoneally in all groups except the control group. Mice in the L-RES, M-RES and H-RES groups were gavaged with RES solution at 25, 50 mg/kg and 100 mg/kg, respectively, 4 h before injection of iron dextran every day; mice in the deferoxamine (DFO) group were injected with DFO intraperitoneally (100 mg/kg); mice in the control group received isovolumetric saline. After seven weeks of RES administration, serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) activities and liver hydroxyproline (Hyp) levels were reduced; the malondialdehyde (MDA) activities decreased and the levels of superoxide dismutase (SOD) and glutathione (GSH) were raised. Hematoxylin and eosin (H&E), Prussian, and Masson staining indicated that RES treatment could improve cell damage and reduce hepatic iron deposition and collagen deposition in iron-overload mice. The expression of Bcl-2 was increased, the expression levels of Bax and caspase-3 were decreased under RES treatment. Moreover, RES reduced the expression of hepcidin, ferritin (Ft), divalent metal transporter-1 (DMT-1), transferrin receptor-2 (TFR-2), and raised the expression of ferroprotein-1 (FPN-1). In conclusion, RES could ameliorate iron overload-induced liver fibrosis, and the potential mechanisms may be related to antioxidant, anti-inflammatory, anti-apoptotic, and more importantly, regulation of iron homeostasis by reducing iron uptake and increasing iron export.

show abstract

Resveratrol prevents liver damage in MCD-induced steatohepatitis mice by promoting SIGIRR gene transcription

Cited by 22 publications

References 27 publications

Human umbilical cord mesenchymal stromal cell-derived exosomes protect against MCD-induced NASH in a mouse model

Human umbilical cord mesenchymal stromal cell-derived exosomes protect against MCD-induced NASH in a mouse model

The Role of Resveratrol in Liver Disease: A Comprehensive Review from In Vitro to Clinical Trials

Resveratrol ameliorates iron overload induced liver fibrosis in mice by regulating iron homeostasis

Contact Info

Product

Resources

About